IP Life Sciences and Advanced Materials

Given the competitive nature of the Life Sciences and Advanced Technology industry, every company operating in those fields needs to manage its intellectual property (IP) to facilitate continued innovation and maintain or grow market share.

Johnson & Johnson has been a BakerHostetler client for well over 25 years. Our many IP projects with J&J have included developing and managing a patent portfolio for a drug treatment now approved by the U.S. Food and Drug Administration and expanding that portfolio to protect continued research and innovation.
To protect combination products and drug regimens in light of inherent bias in the law against such subject matter, we devised exclusivity strategies for J&J’s darunavir patent portfolio and analyzed patent applications and clinical data, developing sophisticated legal arguments for patentability.
We represented Teva Pharmaceuticals in its exclusivity strategies for TREANDA and BENDEKA, used to treat people with chronic lymphocytic leukemia and indolent B-cell non-Hodgkin’s lymphoma. We also helped Teva with exclusivity strategies and patent portfolio development for AUSTEDO, used to treat chorea.
We developed patent portfolio strategies for Tyra Pharmaceuticals, and when the company went public, its IPO raised more than $170 million. We did the same for Prelude Therapeutics, which we have represented since its inception. Prelude’s IPO was also very successful.
Teleflex Inc. manufactures a wide array of medical technologies (including devices) in the vascular, respiratory, cardiac and anesthesia areas, and its products are used in critical care and surgery. We handle all of the company’s patent and trademark prosecution matters across nearly 30 divisions.
We represent RoundTable Healthcare Partners in the IP aspects of numerous pharmaceutical and medical device acquisitions and sales, including its sales of CorePharma LLC and other companies to Impax Laboratories Inc. for $700 million and of Aspen Surgical Products Holdings Inc. to Hill-Rom Holdings Inc. for $400 million.
For medical device company DePuy Synthes, we handle patent prosecution across its range of technologies, including trauma bone plate technology, spinal implants and craniofacial devices. We achieved a favorable settlement of an underlying patent infringement case when the client went through an IPO related to dynamic spinal rods.
We counseled Dicerna Pharmaceuticals in its licensing of Tekmira Pharmaceuticals’ proprietary lipid nanoparticle technology for delivery of one of its RNA interference candidates. This resulted in potentially $24.5 million in milestones, in addition to ongoing royalties.